UK biotechnology company NexaBiome Life Sciences Ltd has received continued funding from Scotland’s national economic development agency, Scottish Enterprise, to accelerate its breakthrough bacteriophage technology for the treatment of diabetic foot infections (DFIs). The funding is the second tranche of support in a £125k project to support the development of a stable, room-temperature wound dressing aimed…
Pioneering UK biotech company NexaBiome has partnered with industry giant, JAFRAL, to propel the development of NexaBiome’s technology for industrial-scale production of immobilised bacteriophage. The agreement signed between the two companies will enable production capacity to be significantly ramped up, with a hundredfold increase – creating the potential to treat millions of patients with phage-based…
UK-based biotechnology company Fixed Phage has changed its name to NexaBiome Limited, pushing forward in its promise to connect science, technology and healthcare to address the global challenge of antimicrobial resistance (AMR), especially in human health. NexaBiome’s pioneering work in addressing bacterial issues will also continue in the animal and veterinary health sector, cementing…
NexaBiome Life Sciences Ltd is an end-to-end biotechnology company focused on addressing the global challenge of antimicrobial resistance and improving human and animal health. The company is based in Glasgow, Scotland, UK.
With significant expertise in addressing bacterial challenges, NexaBiome’s focus is on the discovery, development and provision of effective and sustainable bacteriophage (phage) solutions in the field of human health and animal health.
Bacteriophages are viruses that can target and kill problem bacteria while leaving the beneficial bacteria intact. They are naturally occurring, biodegradable and made from renewable matters.
The company is committed to innovation and harnessing the sustainable power of phage, with its work involving the manufacture, research and development, storage and application of phage, globally.
